AU2020222296B2 - Pharmaceutical combination comprising TNO155 and ribociclib - Google Patents

Pharmaceutical combination comprising TNO155 and ribociclib Download PDF

Info

Publication number
AU2020222296B2
AU2020222296B2 AU2020222296A AU2020222296A AU2020222296B2 AU 2020222296 B2 AU2020222296 B2 AU 2020222296B2 AU 2020222296 A AU2020222296 A AU 2020222296A AU 2020222296 A AU2020222296 A AU 2020222296A AU 2020222296 B2 AU2020222296 B2 AU 2020222296B2
Authority
AU
Australia
Prior art keywords
amino
per day
cancer
tno155
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020222296A
Other languages
English (en)
Other versions
AU2020222296A1 (en
Inventor
Ying-Nan Pan Chen
Huaixiang Hao
Chen Liu
Morvarid MOHSENI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2020222296A1 publication Critical patent/AU2020222296A1/en
Application granted granted Critical
Publication of AU2020222296B2 publication Critical patent/AU2020222296B2/en
Priority to AU2023203751A priority Critical patent/AU2023203751A1/en
Priority to AU2025203816A priority patent/AU2025203816A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020222296A 2019-02-12 2020-02-10 Pharmaceutical combination comprising TNO155 and ribociclib Active AU2020222296B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023203751A AU2023203751A1 (en) 2019-02-12 2023-06-15 Pharmaceutical combination comprising tno155 and ribociclib
AU2025203816A AU2025203816A1 (en) 2019-02-12 2025-05-23 Pharmaceutical combination comprising TNO155 and ribociclib

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804708P 2019-02-12 2019-02-12
US62/804,708 2019-02-12
PCT/IB2020/051031 WO2020165734A1 (en) 2019-02-12 2020-02-10 Pharmaceutical combination comprising tno155 and ribociclib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023203751A Division AU2023203751A1 (en) 2019-02-12 2023-06-15 Pharmaceutical combination comprising tno155 and ribociclib

Publications (2)

Publication Number Publication Date
AU2020222296A1 AU2020222296A1 (en) 2021-08-05
AU2020222296B2 true AU2020222296B2 (en) 2023-04-06

Family

ID=69724013

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2020222296A Active AU2020222296B2 (en) 2019-02-12 2020-02-10 Pharmaceutical combination comprising TNO155 and ribociclib
AU2023203751A Abandoned AU2023203751A1 (en) 2019-02-12 2023-06-15 Pharmaceutical combination comprising tno155 and ribociclib
AU2025203816A Pending AU2025203816A1 (en) 2019-02-12 2025-05-23 Pharmaceutical combination comprising TNO155 and ribociclib

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023203751A Abandoned AU2023203751A1 (en) 2019-02-12 2023-06-15 Pharmaceutical combination comprising tno155 and ribociclib
AU2025203816A Pending AU2025203816A1 (en) 2019-02-12 2025-05-23 Pharmaceutical combination comprising TNO155 and ribociclib

Country Status (13)

Country Link
US (1) US12343344B2 (enExample)
EP (1) EP3923941B1 (enExample)
JP (1) JP7493521B2 (enExample)
KR (1) KR20210126653A (enExample)
CN (1) CN113382731A (enExample)
AU (3) AU2020222296B2 (enExample)
BR (1) BR112021015632A2 (enExample)
CA (1) CA3127286A1 (enExample)
CL (1) CL2021002099A1 (enExample)
IL (1) IL284835B2 (enExample)
MX (1) MX2021009563A (enExample)
TW (1) TWI831916B (enExample)
WO (1) WO2020165734A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839715B (zh) 2018-09-29 2024-12-03 诺华股份有限公司 抑制shp2活性化合物的制造方法
KR20210068472A (ko) 2018-09-29 2021-06-09 노파르티스 아게 Shp2 활성의 억제를 위한 화합물 및 조성물의 제조
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
JP2022519385A (ja) * 2019-02-12 2022-03-23 ノバルティス アーゲー Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
EP4178962B1 (en) 2020-07-08 2025-06-11 Novartis AG Manufacture of compounds and compositions for inhibiting the activity of shp2
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022235822A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
BR112023022819A2 (pt) 2021-05-05 2024-01-16 Revolution Medicines Inc Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
EP4333847A1 (en) * 2021-05-05 2024-03-13 Novartis AG Compounds and compositions for the treatment of mpnst
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202342040A (zh) 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN120504682A (zh) 2022-06-10 2025-08-19 锐新医药公司 大环ras抑制剂
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
KR20240097396A (ko) 2022-12-20 2024-06-27 재단법인대구경북과학기술원 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024253668A1 (en) 2023-04-07 2025-11-13 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
KR20250169290A (ko) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018130928A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331547B1 (en) 2008-08-22 2014-07-30 Novartis AG Pyrrolopyrimidine compounds as cdk inhibitors
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3678703A1 (en) * 2017-09-07 2020-07-15 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
CR20210350A (es) 2018-12-17 2021-09-27 Lunella Biotech Inc Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas
SG11202106532WA (en) 2018-12-17 2021-07-29 Lunella Biotech Inc Triple combination therapies for anti-aging
EP4249000A3 (en) * 2019-02-12 2023-12-27 Novartis AG Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
JP2022519385A (ja) * 2019-02-12 2022-03-23 ノバルティス アーゲー Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018130928A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEMPKE, W.C.M et al., "Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?", ONCOLOGY, 2018, vol. 95, no. 5, pp. 257-269, DOI: 10.1159/000490106 *
Schettini, F. et al., "CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors", FRONTIERS IN ONCOLOGY, 2018, vol. 8, article 608, DOI: 10.3389/fonc.2018.00608 *

Also Published As

Publication number Publication date
AU2020222296A1 (en) 2021-08-05
AU2025203816A1 (en) 2025-06-12
CN113382731A (zh) 2021-09-10
KR20210126653A (ko) 2021-10-20
EP3923941B1 (en) 2025-12-03
IL284835A (en) 2021-08-31
JP7493521B2 (ja) 2024-05-31
WO2020165734A1 (en) 2020-08-20
US20220160707A1 (en) 2022-05-26
AU2023203751A1 (en) 2023-07-13
IL284835B2 (en) 2025-08-01
US12343344B2 (en) 2025-07-01
TWI831916B (zh) 2024-02-11
TW202045171A (zh) 2020-12-16
BR112021015632A2 (pt) 2021-10-05
MX2021009563A (es) 2021-09-08
JP2022519375A (ja) 2022-03-23
IL284835B1 (en) 2025-04-01
CL2021002099A1 (es) 2022-04-18
EP3923941A1 (en) 2021-12-22
CA3127286A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
AU2020222296B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
JP7572958B2 (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
CN115297862A (zh) 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
JP2025529199A (ja) がんの治療で使用するためのｄｃｃ－３１１６とｍａｐｋａｐ経路阻害剤との併用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)